UTRS (Minerva Surgical) FCF Margin %: -42.72% (As of Sep. 2023)


What is Minerva Surgical FCF Margin %?

Minerva Surgical UTRS -99.00% FCF Margin % is -42.72% as of Sep. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Minerva Surgical's Free Cash Flow for the three months ended in Sep. 2023 was $-5.11 Mil. Minerva Surgical's Revenue for the three months ended in Sep. 2023 was $11.97 Mil. Therefore, Minerva Surgical's FCF Margin % for the quarter that ended in Sep. 2023 was -42.72%.

As of today, Minerva Surgical's current FCF Yield % is 0.00%.

The historical rank and industry rank for Minerva Surgical's FCF Margin % or its related term are showing as below:

UTRS' s FCF Margin % Range Over the Past 10 Years
Min: -75.03   Med: 0   Max: 0
Current: -75.03


UTRS's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.1 vs UTRS: -75.03


Minerva Surgical FCF Margin % Related Terms


Minerva Surgical FCF Margin % Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical FCF Margin % Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
FCF Margin %
-76.95 -33.61 -44.07 -70.86

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.06 -112.95 -67.51 -71.85 -42.72

UTRS vs PAVM, ELUT, COCH: FCF Margin % Comparison

For the Medical Devices subindustry, Minerva Surgical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Surgical FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Minerva Surgical's FCF Margin % falls into.



Minerva Surgical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Minerva Surgical's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-35.64/50.294
=-70.86 %

Minerva Surgical's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-5.112/11.965
=-42.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -42.72% mean?
Minerva Surgical (UTRS) has a FCF Margin % of -42.72% as of Sep. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Minerva Surgical and its competitors.
Is Minerva Surgical's FCF Margin % too high?
Minerva Surgical's current FCF Margin % is -42.72%.
How does Minerva Surgical's FCF Margin % compare to PAVM and ELUT?
Minerva Surgical's FCF Margin % of -42.72% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Minerva Surgical and its competitors. Minerva Surgical's current FCF Margin % is -42.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current FCF Margin % of -42.72%. The current FCF Margin % is -42.72%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current FCF Margin % is -42.72% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.